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Abstract
 
In human breast carcinomas, overexpression of the macrophage colony–stimulating factor
(CSF-1) and its receptor (CSF-1R) correlates with poor prognosis. To establish if there is a
causal relationship between CSF-1 and breast cancer progression, we crossed a transgenic
mouse susceptible to mammary cancer with mice containing a recessive null mutation in the
 
CSF-1 gene (
 
Csf1
 
op
 
) and followed tumor progression in wild-type and null mutant mice. The
absence of CSF-1 affects neither the incidence nor the growth of the primary tumors but de-
layed their development to invasive, metastatic carcinomas. Transgenic expression of CSF-1 in
the mammary epithelium of both 
 
Csf1
 
op
 
/Csf1
 
op
 
 and wild-type tumor-prone mice led to an ac-
celeration to the late stages of carcinoma and to a significant increase in pulmonary metastasis.
This was associated with an enhanced infiltration of macrophages into the primary tumor.
These studies demonstrate that the growth of mammary tumors and the development to ma-
lignancy are separate processes and that CSF-1 selectively promotes the latter process. CSF-1
may promote metastatic potential by regulating the infiltration and function of tumor-associ-
ated macrophages as, at the tumor site, CSF-1R expression was restricted to macrophages.
Our data suggest that agents directed at CSF-1/CSF-1R activity could have important thera-
peutic effects.
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Introduction
 
Breast cancer represents the highest incidence and second
leading cause of cancer death in American women (1).
Nonetheless, little is known about the molecular and cellu-
lar factors that contribute to the progression and especially
to the metastasis of this cancer. Normal and malignant
mammary epithelial and their surrounding stromal cells
produce and respond to various growth factors such as
TGF 
 
a
 
 and 
 
b
 
s (2), fibroblast growth factors (FGFs [3]) and
insulin-like growth factors (4). A major effort has been
made to determine the role of such growth factors both in
the normal development and progression to malignancy of
mammary epithelial cells. However, our knowledge of the
factors involved in breast cancer progression, especially in
the interactions between the mammary epithelial, stromal,
and adipose cells, is still limited.
CSF-1 (or macrophage-CSF) is a dimeric polypeptide
growth factor that acts through the cell surface receptor
(CSF-1R) encoded by the 
 
cfms
 
 protooncogene (5). CSF-1
was originally identified as a regulator of the proliferation,
differentiation, and survival of macrophages and their bone
marrow progenitors (5). However, in addition to its nor-
mal role in mononuclear phagocyte biology, elevated ex-
pression of CSF-1 and 
 
cfms 
 
has been found in breast, uter-
ine, and ovarian tumor cells, and the extent of expression
in these tumors correlates with high grade and poor prog-
nosis (6, 7). In breast carcinomas, CSF-1 expression is
prevalent in invasive tumor cells as opposed to the intra-
ductal (preinvasive) cancer (8). The coexpression of CSF-1
and CSF-1R in these cells suggests that CSF-1 might be
involved in tumor invasion through its direct influence on
CSF-1R–bearing tumor cells. However, a strong correla-
tion of CSF-1 expression with dense leukocytic infiltration
that contains a large percentage of CSF-1R–bearing cells
has also been found in human breast carcinomas (8, 9), sug-
gesting that tumor-produced CSF-1 might also be a para-
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crine modifier of host immune function. Solid tumors are
infiltrated by a heterogeneous population of leukocytes of
which macrophages represent a major component (10).
The biological role and possible clinical significance of
these macrophages are still unknown and remained contro-
versial. Studies have shown that macrophages can serve as
both positive and negative mediators of tumor growth (11).
Macrophages are known to mediate direct antitumor cyto-
toxicity and the presentation of tumor-associated antigens
(12, 13). On the other hand, macrophages have also been
found to promote tumor angiogenesis (14) and to secrete a
wide range of growth factors which may promote tumor
growth (15). However, as most of these data are derived
from studies of cultured tumor cells or from clinical obser-
vations, the functions for macrophages in the tumor mi-
croenvironment have still not been determined.
Given the strong association of CSF-1 and CSF-1R ex-
pression with tumor progression and macrophage infiltra-
tion at the tumor site, it is essential to determine the role of
CSF-1 in these processes, especially in the development of
metastatic disease. To address this question, we have estab-
lished a mouse mammary cancer model in the absence of
CSF-1 by breeding the CSF-1 null recessive mutation,
 
Csf1
 
op
 
 
 
(16), onto a mammary cancer–susceptible strain of
mice (polyoma middle T antigen [PyMT]
 
1
 
 mice), in which
the expression of the transgene (Tg), PyMT, was directed
to the mammary epithelium by the mouse mammary tu-
mor virus (MMTV) LTR (17). Previous studies have
shown that in the CSF-1 null mutant (
 
Csf1
 
op
 
/Csf1
 
op
 
) mice,
the development of the myeloid lineage was severely af-
fected with a relative absence of mature macrophages
found in many tissues, including the mammary gland (16,
18). In this study, we demonstrated that in the absence of
CSF-1 the formation and the growth of the primary mam-
mary tumors in PyMT mice was not affected, but the re-
cruitment of macrophages and both the progression to ma-
lignancy and the metastasis of these tumors to the lung
were significantly delayed. Furthermore, restoration of ex-
pression of CSF-1 specifically in the mammary epithelium
of CSF-1 null mutant mice and overexpression of CSF-1 in
wild-type mice using transgenic techniques accelerated
both tumor progression and metastasis.
 
Materials and Methods
 
Mice.
 
All procedures involving mice were conducted in ac-
cordance with National Institutes of Health regulations concern-
ing the use and care of experimental animals. The study of mice
was approved by the Albert Einstein College of Medicine Animal
Use Committee. Detailed descriptions of the origin, care, and
identification of 
 
Csf1
 
op
 
/Csf1
 
op
 
 mice and their heterozygote con-
trols have been given previously (16). 
 
1
 
/
 
Csf1
 
op
 
 mice have nor-
mal serum concentrations of CSF-1, normal tissue populations of
 
macrophages, and are in all aspect tested equivalent to wild-type
(
 
1
 
/
 
1
 
) mice (16). Transgenic mice expressing the PyMT onco-
gene under the control of MMTV LTR were provided by Dr.
W.J. Muller (McMaster University, Ontario, Canada). Male
 
Csf1
 
op
 
/Csf1
 
op
 
 PyMT mice on a C3H/B6 
 
3
 
 FVB-C3H/B6
background were randomly bred with C3H/B6 
 
1
 
/
 
Csf1
 
op
 
 fe-
males lacking the PyMT Tg to obtain female mice heterozygous
for PyMT on either 
 
Csf1
 
op
 
/Csf1
 
op
 
 or 
 
1
 
/
 
Csf1
 
op
 
 background. All
of the mice analyzed in this study were heterozygous for the
PyMT Tg.
The preparation and genotyping of CSF-1–transgenic mice
(MMTV/tetracycline activator [Ta]
 
1
 
 and Tg[CSF-1]
 
1
 
) will be
described in detail separately (unpublished observations). In brief,
the CSF-1 cDNA (19) was ligated downstream of a minimally
active CMV promoter controlled by seven tetracycline operators
in plasmid 609, provided by Dr. L. Hennighausen (Laboratory of
Genetics and Physiology, National Institutes of Health, Bethesda,
MD), and transgenic mice were made by routine methods.
Trangenic mice carrying this construct (Tg[CSF-1]
 
1
 
) were bred
with transgenic mice that expressing the Ta under the control of
the MMTV LTR (MMTV/Ta
 
1
 
; reference 20). Male PyMT
 
Csf1
 
op
 
/Csf1
 
op
 
 MMTV/Ta
 
1
 
 mice on a C3H/B6 
 
3 
 
FVB-C3H/B6
background were crossed with MMTV/Ta
 
1
 
Tg (CSF-1)
 
1
 
 females
in a FVB-C3H/B6 background lacking the PyMT Tg. The ex-
pression of the CSF-1 Tg in the mammary gland was determined
by a reverse transcription (RT)-PCR assay that specifically de-
tects transgenic CSF-1 mRNA. Total mammary gland RNA was
prepared following the guanidium-cesium chloride method (21).
2 
 
m
 
g of total RNA was used for RT following the protocol for
SuperScript II RNase H-Reverse Transcriptase (GIBCO BRL).
Primers used in the PCR reaction were located at the 3
 
9
 
 end of
the CSF-1 cDNA (5
 
9
 
-GGGTGCCTGGTTACATCGGAG-
CAGGGG-3
 
9
 
) and in plasmid 609 (5
 
9
 
-GGGTCCCCAAACT-
CACCCTG-3
 
9
 
). The level of CSF-1 protein in various tissues
was detected by a radioimmunoassay specific for CSF-1 as de-
scribed previously (22).
 
Whole Mount Analysis of Mammary Tumor Growth.
 
Right ab-
dominal mammary glands were used for whole mount prepara-
tion as described (18). Whole mounts were photographed with a
ruler, scanned, and the size of the primary tumor on the Adobe
Photoshop image measured using the NIH Image 1.61 program.
 
5-Bromo-2-deoxy-uridine Incorporation.
 
Female PyMT mice
were injected intraperitoneally with 100 
 
m
 
g/g body wt of
5-bromo-2-deoxy-uridine (BrdU; GIBCO BRL) 2 h before kill-
ing. Left abdominal mammary glands were fixed in formalin,
processed for histology, and BrdU-positive cells detected using a
BrdU Staining Kit (Oncogene Research Products). The entire
primary tumors was scanned into Adobe Photoshop 5 and the
area of BrdU-positive cells, as a fraction of the total scanned area
of the tumor, determined using NIH Image 1.61 with a com-
puter program written to determine the density of staining.
 
Lung Metastasis.
 
Pulmonary metastasis of mammary tumors
in PyMT transgenic mice was determined using Northern analy-
sis for the expression of the Tg, PyMT, in the lung. The lungs
were removed before removing mammary glands to avoid cross-
contamination and RNA was prepared following standard proce-
dures (21). 10 
 
m
 
g of RNA was separated by formaldehyde-aga-
rose gel electrophoresis and blotted onto a nylon filter (21). The
expression of PyMT mRNA was detected using [
 
a
 
-
 
32
 
P]dCTP-
labeled cDNA probes for PyMT, provided by Dr. W.J. Muller
(17), and expression normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; Ambion, Austin, TX). After densitom-
etry, the relative level of PyMT mRNA in the lungs was deter-
 
1
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 BrdU, 5-bromo-2-deoxy-uridine; DIG,
digoxigenin; MMTV, mouse mammary tumor virus; PyMT, polyoma
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mined between samples by normalizing to the level to a control
sample from the mammary gland of a tumor-bearing 
 
1
 
/
 
Csf1
 
op
 
PyMT mouse at 18 wk of age. To identify metastatic mammary
foci, lungs from mammary tumor–bearing mice were fixed in
10% buffer neutralized formalin, sectioned, and stained with he-
matoxylin and eosin.
 
Expression of PyMT in Mammary Epithelium.
 
Northern blots
containing total mammary gland RNA were hybridized with [
 
a
 
-
 
32
 
P]dCTP-labeled cDNA probes for both PyMT and keratin 18
following standard procedures (21). The hybridization signal of
PyMT in each mammary gland was normalized to the keratin 18
signal from the same gland.
 
Histological Analysis and Classification of Mammary Tumors.
 
The left abdominal mammary glands were formalin fixed, sec-
tioned, and stained with hematoxylin and eosin. Primary mam-
mary tumors were classified into four categories by our histo-
pathologist (R.G. Russell), who was unaware of the genotype of
the mice (blinded). These four stages represented the morpho-
logic events of tumor progression from early hyperplasia to ad-
vanced adenocarcinoma and conformed to the recommendations
for classification of mouse mammary tumor pathology (23). (a)
Alveolar hyperplasia: the preneoplastic lesion. The terminal duc-
tal lobular unit comprised of multiple alveoli (acini) branching at
the end of the terminal ducts that were lined by cuboidal cells
with hyperchromatic nuclei and a reduced cytoplasmic to nuclear
ratio. Some acini exhibited orderly, multiple layers of epithelial
cells that partially or completely filled the lumen. At this stage,
the basement membrane of the secretory unit was intact and the
outline of the alveoli distinct. (b) Adenoma: the advance stage of
the premalignant tumor. This stage contained well-differentiated,
multilobulated, and coalescing solid acinar arrangements that
were locally expansile. They were composed of solid sheets of
cells, usually uniform, with basophilic round to oval nuclei. The
outline of the tumor was well defined within the affected lob-
ule(s). (c) Early adenocarcinoma: early malignancy. Tumors were
enlarged, locally expansive, but still well defined. They were
composed of locally coalescing solid acini and lobules with cells
having pleomorphic nuclei and evidence of the loss of an intact
basal lamina. There was a mild increase in connective tissue
stroma, particularly among the periductal and ductal hyperplasias.
Adjacent lobules in the same mammary gland also showed vary-
ing degrees of hyperplasia and adenoma. (d) Late adenocarci-
noma: advanced malignancy. Tumors had extensive neoplastic
nodules composed of multilobulation of solid neoplastic epithelial
cells, sheets of neoplastic cells, poorly differentiated acinar, and
sometimes cribiform arrangements. Elevated mitotic indexes and
prominent rates of apoptosis were observed in some tumors. Nu-
clear atypia and multiple local areas of basement membrane loss
were found. Some tumors showed cystic alveolar spaces contain-
ing protein secretion and lined by irregular multilayered and ir-
regular papillary pleomorphic epithelium.
 
Immunohistochemistry.
 
To identify macrophages at the tumor
site, fomalin-fixed mammary gland sections were immunostained
using the pan-macrophage anti-F4/80 rat monoclonal antibody
(CALTAG Laboratories) and specific reactivity was detected us-
ing a peroxidase-based detection kit (Vector Laboratories) as de-
scribed (18).
 
In Situ Hybridization.
 
Frozen mammary tissues were sec-
tioned and briefly fixed in 4% paraformaldehyde/PBS, embed-
ded, and sectioned. To prepare the 
 
cfms 
 
probes,
 
 
 
plasmid p755 (24)
was linearized by digestion with either SalI or NdeI. Digoxigenin
(DIG)-labeled sense or antisense RNA probe
 
 
 
was synthesized
from the Sp6 or T7 promoter, respectively, in a reaction contain-
 
ing 1 
 
m
 
g of DNA template, using a DIG RNA labeling kit (Boeh-
ringer Mannheim, Leverkusen, FRG).
 
 
 
The hybridization signal
was detected using a DIG Nucleic Acid Detection Kit (Boeh-
ringer). Placental sections (day 14 gestation) were used as a posi-
tive control (25).
 
Results
 
Absence of CSF-1 Does Not Effect Growth of the Primary
Mammary Tumor.
 
To determine the effect of the absence
of CSF-1 on mammary tumor development and progres-
sion, PyMT transgenic mice (PyMT mice), heterozygous
and homozygous for the 
 
Csf1
 
op
 
 mutation (
 
1
 
/
 
Csf1
 
op
 
 and
 
Csf1
 
op
 
/Csf1
 
op
 
), together with nontransgenic control mice
were examined. Mammary tumors were found in all of
PyMT mice as early as 4 wk of age regardless of their back-
ground, consistent with the previous report for wild-type
PyMT mice on an FVB background (17). No mammary
tumors were found in any of the nontransgenic mice, indi-
cating that the development of the tumor was due to the
expression of the PyMT Tg.
The development of tumors in the mammary glands of
both 
 
1
 
/
 
Csf1
 
op
 
 and 
 
Csf1
 
op
 
/Csf1
 
op
 
 PyMT mice has an identi-
cal pattern. At first, a single focus always developed on the
ducts emanating from the nipple (primary tumor [PT]; Fig.
1, A and B). Subsequently, other tumors arose in the ducts
distant to the nipple (Fig. 1 C, open arrowheads). Although
the development of multiple foci on the distal ducts was re-
duced in the 
 
Csf1
 
op
 
/Csf1
 
op
 
 mammary glands (Fig. 1 D), the
rate of growth of the primary tumors was comparable to
that of 
 
1
 
/
 
Csf1
 
op
 
 PyMT mice (Fig. 1, C–E). In both geno-
types, the size of the primary tumor increased linearly from
4 to 10 wk without significant differences in the growth
rate between tumors in 
 
Csf1
 
op
 
/Csf1
 
op
 
 
 
and 
 
1
 
/
 
Csf1
 
op
 
 PyMT
mice (Fig. 1 E). At 12 wk of age in 
 
1
 
/
 
Csf1
 
op
 
 mice, it be-
came impossible to differentiate the primary tumor from
the multiple secondary tumors that had arisen, and data
could not be collected beyond 10 wk. However, in 
 
Csf1
 
op
 
/
Csf1
 
op
 
 mice the area of the primary tumor could be mea-
sured up to 18 wk and the tumor continued to grow lin-
early until this point (Fig. 1 E).
To further determine whether the lack of CSF-1 in
 
Csf1
 
op
 
/Csf1
 
op
 
 
 
PyMT mice inhibited the growth of the tu-
mor cells, the proliferative rate of the primary tumors was
measured by BrdU incorporation (Fig. 1 F). No significant
difference in the distribution and the density of BrdU-pos-
itive cells was found in the primary tumors of 
 
1
 
/
 
Csf1
 
op
 
 and
 
Csf1
 
op
 
/Csf1
 
op
 
 PyMT mice (Fig. 1 F, i, ii, and iii). These re-
sults further demonstrated that the growth of the primary
tumor was not inhibited in the absence of CSF-1.
 
Absence of CSF-1 Resulted in Delayed Lung Metastasis.
We next determined whether pulmonary metastasis of the
mammary tumors in Csf1op/Csf1op PyMT mice was compa-
rable to the 1/Csf1op littermates. Previous studies have
shown that the expression of PyMT mRNA acts as a reli-
able biochemical marker for these metastases (17). The
expression of PyMT mRNA in lungs of Csf1op/Csf1op and
1/Csf1op PyMT mice from 10 to 22 wk was examined by730 Colony Stimulating Factor 1 Promotes Tumor Progression to Malignancy
Figure 1. Growth of mammary tumors was
not inhibited in Csf1op/Csf1op PyMT mice. (A–D)
Representative mammary whole mounts of
1/Csf1op  (A and C) and Csf1op/Csf1op PyMT
mice (B and D) at ages indicated (original magni-
fication:  32.5). PT, the primary tumor in the
nipple area; LN, the subiliac lymph node. Black
arrowheads point to terminal-end buds and open
arrowheads point to the tumor foci on ducts distal
to the nipple. (E) Growth of primary mammary
tumors in 1/Csf1op (j; n 5 30) and Csf1op/Csf1op
(s; n 5 53) PyMT mice was measured in mam-
mary whole mounts at the age indicated. Data are
presented as the mean 6 SE of at least four mice
per group. No significant difference was found
between the two groups at 4, 6, 8, and 10 wk
(unpaired Student’s t test). (F) Cell proliferation
in primary tumors was determined by BrdU in-
corporation. Typical distribution of BrdU-posi-
tive cells (brown spots) in mammary tumor of
1/Csf1op (i) and Csf1op/Csf1op (ii) PyMT mice at
8 wk of age (original magnification: 3100); (iii)
comparison of densities of BrdU positive cells in
primary tumors of 1/Csf1op and Csf1op/Csf1op
PyMT mice at 8 wk of age. No significant differ-
ence was found (unpaired Student’s t test, n 5 8).
In this and other figures, 1/op and op/op indicate
1/Csf1op and Csf1op/Csf1op, respectively.731 Lin et al.
Northern analysis corrected for RNA loading by expres-
sion of the housekeeping GAPDH gene. In 10–14-wk-old
1/Csf1op mice a very low level of PyMT mRNA was de-
tected in the lungs. By 18 wk of age this expression in-
creased z20-fold (P 5 0.048) and increased a further
8-fold by 22 wk of age (Fig. 2 A). The metastasis of the
mammary tumor in 1/Csf1op PyMT transgenic mice was
confirmed by histological analysis that showed small colo-
nies of mammary tumor cells growing in the lung (Fig. 2
B). In contrast, only baseline levels of PyMT mRNA were
found in lungs of Csf1op/Csf1op mice examined over the
same period with the exception of one mouse at 20 wk that
showed significant expression of PyMT mRNA (Fig. 2 A).
A significant difference in PyMT mRNA level in the lung
was found between 1/Cf1op and Csf1op/Csf1op mice at 18
to 22 wk (P , 0.0001; Fig. 2 A). No metastatic lesions
were found in Csf1op/Csf1op PyMT lungs after histologic
examination of a limited number of samples. These results
show that by these measurements the metastasis of the
mammary tumors to the lung in Csf1op/Csf1op PyMT mice
was delayed compared with 1/Csf1op littermates.
One trivial explanation for the lower rate of tumor pro-
gression and metastasis in Csf1op/Csf1op mice is that the Tg,
PyMT, is not expressed at the same level in Csf1op/Csf1op
and  1/Csf1op PyMT mammary epithelium. Therefore,
Northern analysis was performed to compare the level of
PyMT mRNA in the mammary glands of these mice at
various ages. To correct for the variable epithelial cell con-
centrations in the 1/Csf1op and Csf1op/Csf1op  mammary
glands, PyMT mRNA level in each mammary gland was
normalized to the expression of the mRNA for keratin 18,
an intermediate filament expressed in simple epithelia and
their tumor cells (26). No significant difference was found
in the PyMT mRNA levels in 1/Csf1op and Csf1op/Csf1op
mammary glands (Fig. 2 C), suggesting that mammary epi-
thelial and tumor cells in these mice express similar levels of
PyMT.
Histopathological Progression of the Mammary Tumor in
Csf1op/Csf1op Mice Is Delayed. To investigate the basis for
the delayed metastasis in Csf1op/Csf1op mice, the histology
of the primary mammary tumors in PyMT mice was evalu-
ated in a blinded fashion. The development of the tumor
was classified into four histopathological stages, as described
in Materials and Methods, from the nonmalignant alveolar
hyperplasia and adenoma to the malignant early and late
adenocarcinoma. A similar distribution of histopathological
stages was found in 1/Csf1op and Csf1op/Csf1op primary tu-
mors from 4 to 8 wk of age (Fig. 2 D). Over this age range,
the majority of mice in either background developed non-
malignant hyperplasia and adenomas. However, a dramatic
progression of the tumor to malignant stages, especially to
the most advanced invasive late carcinoma stage, occurred
in 1/Csf1op mice beginning at 10 wk of age. 50% of
1/Csf1op PyMT mice examined at 10 wk had primary tu-
mors that had developed to the most malignant late carci-
noma stage, whereas none of the 2 wk younger 1/Csf1op
PyMT mice had progressed to this stage (P 5 0.0087; Fig 2
D, indicated by *). On the other hand, only 13% of Csf1op/
Figure 2. Histopathological progression and metastasis of mammary tu-
mors in Csf1op/Csf1op PyMT mice was delayed. (A) Pulmonary metastasis
of mammary tumors in 1/Csf1op and Csf1op/Csf1op PyMT mice was com-
pared by Northern analysis of PyMT mRNA expression in lungs. Data
are presented as the mean 6 SE of at least three mice for each time point.
Asterisk indicate the significant difference of 1/Csf1op PyMT mice be-
tween 10 to 14 and 18 to 22 wk of age (Mann-Whitney test, P 5 0.0016,
n 5 21), and the significant difference between 1/Csf1op and Csf1op/
Csf1op PyMT mice from 18 to 22 wk of age (Mann-Whitney test, P ,
0.0001, n 5 28). (B) Hematoxylin and eosin–stained lung section from a
1/Csf1op PyMT mouse at 18 wk of age (original magnification: 3100).
(C) PyMT mRNA levels in mammary gland epithelium of 1/Csf1op and
Csf1op/Csf1op PyMT mice from 6 to 12 wk of age were compared using
Northern analysis. Mean 6 SE of eight mice/group. No significant differ-
ence was found between the two groups (unpaired Student’s t test). (D)
Histopathological progression of primary tumors to late carcinoma in
Csf1op/Csf1op PyMT mice was delayed compared with 1/Csf1op litter-
mates. Data are presented as the percentile distribution of primary tumors
of 1/Csf1op (n 5 68) and Csf1op/Csf1op PyMT mice (n 5 70) in four his-
topathological stages at the ages indicated. Asterisks indicate a significant
difference in the frequency of late carcinoma stage tumors in mice older
than 8 wk of age compared with mice of the same genotype at 8 wk of
age (Fisher’s exact test, P 5 0.0087, 0.0004, and 0.0006 for 1/Csf1op and
P 5 0.42, 0.077, and 0.0006 for Csf1op/Csf1op PyMT mice at 10, 16, and
22 wk of age, respectively).732 Colony Stimulating Factor 1 Promotes Tumor Progression to Malignancy
Csf1op PyMT mice examined at 10 wk of age had devel-
oped to the late carcinoma stage, which was not a signifi-
cant increase compared with the Csf1op/Csf1op PyMT mice
examined at 8 wk of age (P 5 0.42; Fig. 2 D). In fact,
compared with Csf1op/Csf1op PyMT mice at 8 wk, a signif-
icant increase of primary tumor to the late carcinoma stage
did not occur in Csf1op/Csf1op PyMT mice until these mice
reached 22 wk of age (Fig. 2 D, indicated by *). These data
Figure 3. Infiltration of leukocytes and
F4/801 cells at the tumor site was reduced
in Csf1op/Csf1op PyMT mice.  (A–D) Pri-
mary tumors in PyMT mice at 7 wk of age.
Hematoxylin and eosin–stained 1/Csf1op
(A) and Csf1op/Csf1op (B) tumors (original
magnification: 3100). Arrowheads indicate
infiltrated leukocytes. The insets in A and B
are shown in C and D as adjacent sections
immunostained with anti-F4/80 mono-
clonal antibody (original magnification:
3250). (E and F) Hematoxylin and eosin–
stained primary tumors from 1/Csf1op (E)
and Csf1op/Csf1op (F) PyMT mice at 9 wk.
Arrows indicate the site at which the tumor
acini adjacent to zones of leukocyte infiltra-
tion display disrupted boundaries (original
magnification: 3400). (G–J) Primary mam-
mary tumors at late adenocarcinoma stage.
(G and H) Hematoxylin and eosin–stained
mammary primary tumors; (I and J) adjacent
sections immunostained with anti-F4/80
monoclonal antibody from 1/Csf1op and
Csf1op/ Csf1op PyMT mice at 19 and 20 wk
of age, respectively (original magnification:
3250). T, tumor; S, stroma.733 Lin et al.
indicate that the tumor progression to this most aggressive
carcinoma stage in Csf1op/Csf1op PyMT mice was .10 wk
delayed compared with 1/Csf1op littermates (Fig. 2 D).
Paucity of Tumor-associated Macrophages Is Correlated
with Delayed Tumor Progression. CSF-1 is a macrophage
growth factor, suggesting that the recruitment of macro-
phages to the tumor might be a factor that promotes the
aggressive development of the 1/Csf1op tumors. Conse-
quently, we examined the histology of the mammary
tumors and the surrounding stroma from both 1/Csf1op
and Csf1op/Csf1op PyMT mice at the period of the transi-
tion to carcinoma (z10 wk of age). Before the transition at
7 to 8 wk of age, a dramatic increase of leukocytic infiltra-
tion was found around the primary mammary tumors in
1/Csf1op mammary glands (Fig. 3 A, indicated by arrows).
No such increase was observed at the tumor site in Csf1op/
Csf1op mammary glands (Fig. 3 B), though the primary tu-
mors in both Csf1op/Csf1op and 1/Csf1op PyMT mice had
progressed to similar nonmalignant stages (adenoma). Im-
munohistochemical analysis, using a monoclonal antibody
against the macrophage lineage–specific marker, F4/80,
showed that a large percentage of infiltrated leukocytes in
the 1/Csf1op mammary gland were F4/80 positive (Fig. 3
C) and that few such cells were found around Csf1op/Csf1op
primary tumors (Fig. 3 D). In concert with the histopatho-
logical development of the primary tumors to the carci-
noma stage, the infiltration of leukocytes became more in-
tense and focal infiltration sites were often seen in the
mammary glands of 1/Csf1op PyMT mice. Densely infil-
trated cells with the morphology of granulocytes, mast
cells, and monocyte-like cells were found in these sites and
the tumor acini adjacent to them often displayed a dis-
rupted boundary (Fig. 3 E, arrows). This suggests that the
basement membrane of the acini at the infiltration site had
lost its integrity, potentially allowing tumor cells to migrate
into the adjacent connective tissue. These leukocytic infil-
tration sites were detected in 1/Csf1op PyMT mice as early
as 9 wk of age but were absent in Csf1op/Csf1op mammary
glands at the same age (Fig. 3 F). Furthermore, an intensive
infiltration of F4/801 cells was found in the vicinity of
1/Csf1op tumor that had developed to the carcinoma stage
(Fig. 3, G and I), whereas the density of F4/801 cells was
still reduced in Csf1op/Csf1op tumors, even in those that had
developed to the same histological stage (Fig. 3, H and J).
These results are consistent with the hypothesis that
CSF-1 acts through macrophages in its promotion of tu-
mor progression. However, in human mammary tumor,
CSF-1 receptor expression has been detected in tumor cells
as well as infiltrated macrophages (8). To determine if mac-
rophages are the only target cell at the tumor site in mice,
we performed in situ hybridization for CSF-1R expression.
CSF-1R–positive cells were found to be in the infiltrated
cells surrounding the tumor in 1/Csf1op mammary glands
but the tumor cells were consistently negative (Fig. 4 A, ii).
The positively stained cells were mononuclear, dendritic
cells with elongated cell bodies, and were in the same loca-
tion as F4/801 cells consistent with their identification as
macrophages (Fig. 4 A, iii). Very few positive cells were
found when the same cfms antisense probe was hybridized
to tumor-bearing Csf1op/Csf1op mammary glands (data not
shown). The sense cfms probe on adjacent 1/Csf1op mam-
mary gland sections was consistently negative (Fig. 4 A, i).
To obtain a quantitative comparison of macrophage infil-
tration in the mammary tumors of Csf1op/Csf1op and
1/Csf1op PyMT mice, the expression of cfms was deter-
mined by Northern analysis. Expression of cfms mRNA was
detected in 1/Csf1op mammary glands and an approximately
threefold increase of the mRNA was observed at 6 wk
compared with 4 wk of age (Fig. 4 B). The cfms mRNA in
Csf1op/Csf1op mammary gland was barely detectable until
12 wk, at which age the level of cfms mRNA was less than
the level found in 1/Csf1op mammary glands at 4 wk of
age (Fig. 4 B). As all mononuclear phagocytes express the
CSF-1R, this data is consistent with both the F4/801 im-
Figure 4. Expression of CSF-1R was found in macrophage-like cells. (A) CSF-1R ex-
pressing cells at the tumor site were identified by in situ hybridization for cfms. Primary
mammary tumor from a 1/Csf1op PyMT mouse at 14 wk of age was hybridized with sense
(i) and antisense (ii) cfms probes, respectively (original magnification: 3250). The inset in
panel (ii) is shown in panel (iii; original magnification: 31,000). Arrows indicate positively
stained cells. (B) Northern analysis of cfms mRNA in mammary glands of 1/Csf1op and
Csf1op/Csf1op PyMT mice at the ages indicated. Et-Br, the same gel stained with ethidium
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munohistochemistry and the sole localization of the CSF-
1R in macrophages.
Transgenic Expression of CSF-1 in Csf1op/Csf1op Mammary
Epithelium Accelerates Tumor Progression. To determine
whether the progression and metastasis of mammary tu-
mors in PyMT mice can be affected by CSF-1 produced
locally in the mammary gland, transgenic mice expressing
CSF-1 specifically in the mammary epithelium were pre-
pared. The transgenic construct consisted of the full-length
CSF-1 cDNA which encodes predominately the secretory
form of CSF-1 (19). The CSF-1 cDNA was ligated down-
stream of a minimally active CMV promoter controlled by
tetracycline operators (Fig. 5 A, a), and the transgenic mice
carrying this construct (Tg[CSF-1]1)were bred with mice
that expressed the transgenic Ta under the control of
MMTV LTR (MMTV/Ta1; reference 20). The progeny
having both these Tgs, MMTV/Ta1 and Tg(CSF-1)1, ex-
press CSF-1 specifically in mammary and salivary glands
(unpublished observations). The expression of the Tg in
the mammary glands of CSF-1 transgenic mice (MMTV/
Ta1Tg[CSF-1]1) was detected by RT-PCR (Fig. 5 A, b;
lanes 7 and 8) but was not found in the mice only carrying
the tetracycline transactivator (MMTV/Ta1; Fig. 5 A, b;
lanes 3–6). Using a radioimmunoassay specific for CSF-1
(22), the concentration of CSF-1 protein in the mammary
gland lysates of CSF-1–transgenic Csf1op/Csf1op  PyMT
mice was comparable to nontransgenic 1/Csf1op PyMT
controls (data not shown). At 8 wk of age, z43 pg/mg of
CSF-1 protein was found in the mammary gland of CSF-
1–transgenic Csf1op/Csf1op  PyMT mice, a level that was
similar to 1/Csf1op PyMT controls at 18 wk (31 pg/mg).
More than a twofold increase of CSF-1 protein concentra-
tion was found in the mammary gland of transgenic Csf1op/
Csf1op PyMT mice examined at 18 wk of age. Unlike non-
Figure 5. Progression of mammary tumor
to malignancy was accelerated in CSF-1–
transgenic Csf1op/Csf1op PyMT mice. (A, a)
Schematic diagram of CSF-1 transgenic
construct. CSF-1 cDNA was ligated down-
stream of a CMV promoter controlled by
tetracycline operators, TetO. SV40An,
polyadenylation site from SV40 small t anti-
gen; X, restriction site for XbaI, Bam, re-
striction site for BamHI; Bgl, restriction site
for BglII. (A, b) RT-PCR analysis of trans-
genic CSF-1 expression in mammary glands.
RNA samples were analyzed from four
nontransgenic control (lanes 3–6), two CSF-
1–transgenic (lanes 7 and 8), and the same
CSF-1–transgenic PyMT mice without re-
verse transcriptase (lanes 1 and 2). Lane 9,
genomic DNA from a CSF-1–transgenic
mouse. CSF-1 Tg, positive 300-bp band.
(B) Histopathological distribution of pri-
mary mammary tumors in CSF-1–trans-
genic and control Csf1op/Csf1op PyMT mice
at 18 wk of age. Data are presented as the
percentile distribution of four histopatho-
logical stages of primary mammary tumors
in CSF-1–transgenic (Tg1, n 5 6) and con-
trol (Tg2, n 5 10) Csf1op/Csf1op  PyMT
mice. Asterisk indicates a significant differ-
ence in the frequency of late carcinoma
stage tumors between CSF-1–transgenic and control Csf1op/Csf1op PyMT mice (Fisher’s exact test, P 5 0.039). (C) Pulmonary metastasis of mammary tu-
mors in CSF-1–transgenic Csf1op/Csf1op and control PyMT mice at 18 wk of age were compared by Northern analysis of PyMT mRNA expression in
lung. Data are presented as the mean 6 SE of at least five mice/point. Asterisks indicate significant differences for both CSF-1–transgenic Csf1op/Csf1op
(Tg1, n 5 6) and control 1/Csf1op PyMT mice (n 5 5) when compared with control Csf1op/Csf1op PyMT mice (n 5 6) (Mann-Whitney test, P 5 0.03
and 0.008, respectively). No significant difference was found between CSF-1–transgenic Csf1op/Csf1op and control 1/Csf1op PyMT mice at the same age
(Mann-Whitney test, P 5 0.33). (D–G) Histology of mammary tumors from CSF-1–transgenic (E and G) and control (D and F) Csf1op/Csf1op PyMT
mice at 18 wk of age. Stained with hematoxylin and eosin (D and E) and with anti-F4/80 antibody (F and G; original magnification: 3250).735 Lin et al.
transgenic 1/Csf1op PyMT control mice, no CSF-1 pro-
tein was detected in the serum of CSF-1–transgenic Csf1op/
Csf1op PyMT mice and the extended estrous cycle found in
Csf1op/Csf1op mice (27) was not corrected in these CSF-1–
transgenic mice. This indicates the expression of CSF-1 is
restricted to mammary and does not result in a general cor-
rection of phenotype (unpublished observations).
To determine whether restoration of CSF-1 expression
in Csf1op/Csf1op mammary glands could accelerate tumor
progression, MMTV/Ta1Tg(CSF-1)1 mice were bred
onto  Csf1op/Csf1op PyMT mice. Enhanced tumor progres-
sion was found in these CSF-1–transgenic Csf1op/Csf1op
PyMT mice. Primary mammary tumors in all of the six
CSF-1–transgenic Csf1op/Csf1op PyMT mice examined at
z18 wk had developed to late carcinoma, whereas only
40% (4 out of 10) control Csf1op/Csf1op PyMT mice exam-
ined at this age had tumors of this stage (P 5 0.039; Fig. 5
B). This histopathological distribution in CSF-1–transgenic
mice was identical to that found in the 1/Csf1op PyMT
controls mice at a comparable age. Pulmonary metastasis
had occurred in CSF-1–transgenic Csf1op/Csf1op PyMT
mice by 18 wk of age in a fashion similar to 1/Csf1op con-
trol PyMT mice. The mean level of PyMT mRNA in
lungs of 18-wk-old CSF-1–transgenic Csf1op/Csf1op PyMT
mice was .100-fold higher than the Csf1op/Csf1op PyMT
controls (P 5 0.03) and not significantly different from the
level in 1/Csf1op lungs at the same age (P 5 0.33; Fig. 5
C). A marked increase of F4/801 cells was found in the
mammary tumors of these CSF-1–transgenic Csf1op/Csf1op
mice (Fig. 5, E and G) compared with the control Csf1op/
Csf1op mice that had developed to the same carcinoma stage
(Fig. 5, D and F). The distribution of F4/801 cells in CSF-
1–transgenic Csf1op/Csf1op PyMT mice had a different ap-
pearance from the infiltration pattern found in 1/Csf1op
PyMT control mice. In the CSF-1–transgenic Csf1op/Csf1op
carcinomas, patches of intensive infiltration were adjacent
to areas lacking infiltrated cells whereas in 1/Csf1op control
carcinomas, F4/801 cells were often evenly distributed
throughout the tumor. These findings are consistent with
reports that the expression of the MMTV promoter is mo-
saic in mammary epithelium (20).
Transgenic Expression of CSF-1 in  1/Csf1op Mam-
mary  Gland Accelerates Tumor Progression. We next asked
whether local overexpression of CSF-1 could drive tumor
progression in 1/Csf1op PyMT mice that are phenotypi-
cally normal with respect to the serum CSF-1 level and
hematopoietic and mammary gland development (16). We
found that both the local progression of the tumor in the
mammary gland and pulmonary metastases in these mice
were greatly accelerated. At 8 wk of age, a significant ad-
vance in tumor histology was found in the CSF-1–trans-
genic 1/Csf1op PyMT mice (Fig. 6 A). Seven out of nine
primary tumors of the CSF-1–transgenic 1/Csf1op PyMT
mice examined at 8 wk were at the carcinoma stage, com-
pared with only 2 out of 14 1/Csf1op control PyMT mice
at this age (P 5 0.0066; Fig. 6 A). The density of infiltrat-
ing leukocytes and F4/801 cells in the mammary glands of
CSF-1–transgenic 1/Csf1op PyMT mice was also greater
than in control 1/Csf1op PyMT mice, and this infiltration
occurred much earlier in the transgenic mice compared
with the nontransgenic controls. A high density of F4/801
cells was found in the vicinity of mammary tumors in the
Figure 6. Tumor progression
was accelerated in CSF-1–trans-
genic 1/Csf1op PyMT mice. (A)
Histopathological distribution of
primary mammary tumors in
CSF-1–transgenic and control
1/Csf1op PyMT mice at 8 wk of
age. Data are presented as the
percentile distribution of histo-
pathological stages of primary
mammary tumors in CSF-1–
transgenic (Tg1, n 5 9) and
control  1/Csf1op PyMT mice (Tg2, n 5 14). Asterisks indicate a signifi-
cant difference in the frequency of carcinoma stage tumor between CSF-
1–transgenic and control 1/Csf1op PyMT mice (Fisher’s exact test, P 5
0.007). (B–E) Tumor histology and the distribution of F4/801 cells in tu-
mors of control (B and D) and CSF-1–transgenic (C and E) 1/Csf1op
PyMT mice at 5 wk of age. (B and C) Hematoxylin and eosin staining; (D
and E) the adjacent sections stained with anti-F4/80 monoclonal antibody.
Arrows indicate areas with high density of F4/80 cells. (F) Pulmonary me-
tastasis of mammary tumors in CSF-1–transgenic and control 1/Csf1op
PyMT mice at 13 and 14 wk of age were compared by Northern analysis
of PyMT mRNA expression in lung. Data are presented as the mean 6 SE
of at least three mice/point. Asterisks indicate a significant difference be-
tween CSF-1–transgenic 1/Csf1op PyMT mice at 13 wk (Tg1) and con-
trol 1/Csf1op PyMT mice at 14 wk of age (Tg2) (Mann-Whitney test,
P 5 0.029).736 Colony Stimulating Factor 1 Promotes Tumor Progression to Malignancy
CSF-1–transgenic 1/Csf1op PyMT mice as early as 5 wk of
age (Fig. 6, C and E), whereas very few infiltrates were
seen in the control 1/Csf1op PyMT mice at this age (Fig.
6, B and D). Compared with 14-wk-old control 1/Csf1op
PyMT mice a significantly higher level of PyMT mRNA
was found in lungs of CSF-1–transgenic 1/Csf1op PyMT
mice at 13 wk of age (Fig. 6 F; P 5 0.029). As only a basal
level of PyMT mRNA was found in the lungs of control
1/Csf1op PyMT mice until 18 wk of age (Fig. 2 A), this
result indicates that the lung metastasis of the mammary tu-
mor in CSF-1–transgenic 1/Csf1op PyMT mice occurred
several weeks earlier than in the nontransgenic 1/Csf1op
controls. Thus, local overexpression of CSF-1 not only re-
sulted in an enhancement of tumor progression in Csf1op/
Csf1op PyMT mice but also accelerated this process in
wild-type PyMT mice expressing normal level of systemic
CSF-1.
Discussion
The transition from the normal to a malignant state is a
multistep process involving genetic and epigenetic changes.
Alterations in cellular regulatory circuits have been identi-
fied during this progression (28). Many tumor cells produce
growth factors and/or their receptors, such as platelet-
derived and vascular endothelial growth factor and TGF-a
produced by glioblastomas and sarcomas (29, 30), fibroblast
growth factor 2 by melanomas (31), and epidermal growth
factor (EGF) receptor or HER-2/neu overexpressed in
breast carcinomas (32). Signaling pathways that are in-
volved in the transduction of mitogenic stimuli, such as the
mitogen-activated protein (MAP) kinase and the phos-
phatidylinositol (PI)-3 kinase pathways, are often constitu-
tively activated in tumor cells (33, 34), while upregulated
expression of antiapoptotic genes also occurs frequently
(35). All of these alterations enable tumor cells to elude the
commitment to terminal differentiation and quiescence
that normally regulate tissue homeostasis. However, little is
known about how these cells exhibiting uncontrolled pro-
liferation or increased life span become malignant and able
to metastasize to a distant organ, a feature that differentiates
them from benign tumor cells. Many genes specifically ex-
pressed in malignant tumors have been identified. How-
ever, only a very few of these have been shown to influ-
ence the acquisition of invasiveness and metastatic potential
(36). In this paper we demonstrate that CSF-1 is one such
regulatory factor that has no effect on mammary tumor ini-
tiation and growth but promotes tumor progression to ma-
lignancy.
Clinically, overexpression of CSF-1 and CSF-1R has
been found in a large percentage of breast cancers where
expression is correlated with poor prognosis (6). In these
tumors, CSF-1R was expressed in both tumor cells and in-
filtrating macrophages (8). A marked leukocytic infiltration
in these tumors also correlated with poor prognosis with
the majority of these cells being macrophages (8, 37). CSF-1
is the major growth factor for the mononuclear phagocytic
lineage and is a chemoattractant for these cells (5, 38).
Consequently we proposed that CSF-1 might not only act
as an autocrine factor for tumor cells but also to recruit
macrophages to the tumor site where they promote the
progression of the tumor (39).
To test whether CSF-1 has a causal role in mammary tu-
morigenesis, we established a mouse model whereby a tu-
mor-prone mouse strain was made homozygous or het-
erozygous for a recessive null mutation in the CSF-1 gene,
and the effect of the absence of CSF-1 on tumor progres-
sion analyzed. This model more likely mimics the situation
in humans, as the tumor develops within the natural mam-
mary environment and all of the factors involved in tumor
progression and metastasis are present in the environment.
In contrast, previous studies have mainly focused on direct
effects of CSF-1 on cultured tumor cells. In these studies,
or in tumor cells transplanted into immuocompromised
mice models, both positive and negative effects of CSF-1
have been reported (40–43). However, our data clearly in-
dicates that the absence of CSF-1, although not affecting
the incidence or growth of the primary tumor, dramatically
reduced its progression to malignancy as assessed by tumor
morphology and lung metastasis. A caveat to this interpre-
tation is that the necessary breeding results in a mixing of
genetic backgrounds that could potentially expose a modi-
fier gene that might affect the rate of tumor progression.
However, our closed colony was randomly bred to ensure
that independently segregating genes would be randomly
assorted to each genotype. Thus, although modifier genes
might increase the data variance, they would not affect the
final conclusion, as this breeding strategy ensures that such
genes would not be enriched in a particular genotype. Fur-
thermore, restoration of CSF-1 specifically in the mam-
mary gland but not elsewhere except the salivary gland,
accelerated mammary tumor progression and increased
metastasis. This treatment did not restore serum CSF-1
concentrations in the null mutant mice, or rescue other
phenotypes including the extended estrous cycles, osteo-
petrosis, nor tissue populations of macrophages other than
in the mammary gland (unpublished observations). Fur-
thermore, overexpression of CSF-1 in 1/Csf1op mice also
accelerated mammary gland progression to the metastatic
state despite the normal CSF-1 serum and tissue concentra-
tions in these mice. These data argues strongly that the ef-
fects of CSF-1 on tumor progression are not secondary to
some other phenotype in the mutant mice but are directly
due to a requirement in the tumor. They also argue
strongly that CSF-1 will have a causal role in tumor pro-
gression in humans and that this explains the correlation
between CSF-1 overexpression and poor prognosis.
In 1/Csf1op PyMT mice, a transition point of the pri-
mary mammary tumor to malignancy was identified at 10
wk of age when there was a significant increase in the
number of mice that developed late carcinomas, followed
by pulmonary metastases at 18 wk of age. This transition to
carcinoma was preceded by recruitment of abundant mac-
rophages to the tumor. In contrast, in CSF-1 null mutant
PyMT mice, macrophage infiltration at the tumor site was
not observed and both malignant transition and pulmonary737 Lin et al.
metastasis were markedly delayed. In addition, increased
macrophage density at the tumor site was associated with
accelerated tumor progression and metastasis in both
Csf1op/Csf1op  and  1/Csf1op PyMT mice expressing the
CSF-1 Tg in the mammary gland. In this mouse model, in
contrast to human tumors, CSF-1R expression could only
be detected in macrophages and not in the tumor cells. Al-
though it cannot be completely ruled out that tumor cells
could also express CSF-1R mRNA at a level below detec-
tion in our experiments, our data strongly argues that mac-
rophages are the only target for CSF-1 action. In humans,
CSF-1 is also expressed in the tumor cells. However, in
mice, analysis of CSF-1 transcripts in the mammary gland
and their tumors showed a low level of expression that was
not enriched as the tumors grew (data not shown). This
suggests that the lack of macrophages in the tumors of
Csf1op/Csf1op mice is due primarily to the systemic loss of
CSF-1 leading to few circulating monocytes, and that in
mice there are chemoattractants other than CSF-1 which
recruit macrophages to the tumor site. Nevertheless, as
CSF-1 is found in serum and mammary tissue under nor-
mal circumstance, these macrophages will be exposed to
CSF-1.
Overall, our data suggests a role for infiltrated macro-
phages in the progression to malignancy. The biological basis
of this is unknown. However, we observed high densities
of macrophages at sites where the basement membrane of
the acini had lost its integrity. Macrophages are potent pro-
ducers of proteases and, at least, plasminogen activator is
CSF-1–regulated in these cells (44). Macrophages also pro-
duce many angiogenic factors, including thymidine phos-
phorylase and vascular endothelial–derived growth factor
(VEGF), suggesting that these could also promote this es-
sential process for metastasis (45). Macrophages are also ma-
jor producers of growth factors (46) such as epidermal
growth factor that could act as a paracrine factor on tumor
cells promoting their migration and invasion through the
acinar basement membrane and into blood vessels (15).
However, given the extraordinary range of product that
macrophages can synthesize, it seems likely that macro-
phages play multifunctional roles in the progression of
mammary tumors.
The dramatic reduction in tumor progression and me-
tastasis in the absence of CSF-1 represents the first occasion
in which histological progression and metastasis have been
coordinately modulated in the PyMT breast cancer model.
Pulmonary metastasis was found to be reduced in Mgat5-
deficient PyMT mice. However, the effect on metastasis
could be attributed to an inhibitory effect of Mgat5 defi-
ciency on the growth of the primary tumor (47). Modified
tumor organization and increased infiltration of mono-
cytes/macrophages at the tumor site were observed in ten-
ascin-C–deficient PyMT mice; however, neither metastasis
nor primary tumor progression were altered in the mice
(48). Suppression of pulmonary metastasis was observed in
plasminogen-deficient PyMT transgenic mice in the ab-
sence of effect on the growth of primary mammary tumor
(49). However, no histological difference was detected
between tumors in plasminogen-deficient and wild-type
mice: all tumors presented as well differentiated adenocar-
cinomas (49). The age range (10–20 wk) of mice in the lat-
ter study was similar to that in the current report, suggest-
ing that the histological defect observed in Csf1op/Csf1op
PyMT mice is a specific feature of CSF-1 deficiency and
may reflect CSF-1–dependent steps that are antecedent to
those affected by plasminogen.
In conclusion, this study has identified CSF-1 as an im-
portant regulatory factor in mammary tumor progression to
metastasis, possibly acting through macrophages. These
data in mice have provided a causal explanation for the cor-
relation between poor prognosis in breast cancer patients
with CSF-1 overexpression and leukocytic invasion into
the tumor. Consequently, therapeutics targeted at CSF-1
or the CSF-1R could potentially benefit patients.
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